BGM Group Ltd. (BGM)

Market Cap	953.76M
Revenue (ttm)	25.10M
Net Income (ttm)	-1.44M
Shares Out	97.22M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,240
Open	10.09
Previous Close	9.80
Day's Range	9.76 - 10.10
52-Week Range	1.78 - 14.78
Beta	1.42
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 4, 2025

About BGM

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 12, 2021
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: BGM
• Website: https://www.bgmgroupltd.com

Financial Performance

In 2024, BGM Group's revenue was $25.10 million, a decrease of -45.99% compared to the previous year's $46.47 million. Losses were -$1.44 million, -81.46% less than in 2023.

Financial numbers in USD